Journal article 622 views 127 downloads
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
Malcolm D. Mason,
Noel W. Clarke,
Nicholas D. James,
David P. Dearnaley,
Melissa R. Spears,
Alastair W.S. Ritchie,
Gerhardt Attard,
William Cross,
Rob J. Jones,
Christopher C. Parker,
J. Martin Russell,
George N. Thalmann,
Francesca Schiavone,
Estelle Cassoly,
David Matheson,
Robin Millman,
Cyrill A. Rentsch,
Jim Barber,
Clare Gilson,
Azman Ibrahim,
John Logue,
Anna Lydon,
Ashok D. Nikapota,
Joe M. O’Sullivan,
Emilio Porfiri,
Andrew Protheroe,
Narayanan Nair Srihari,
David Tsang,
John Wagstaff,
Jan Wallace,
Catherine Walmsley,
Mahesh K.B. Parmar,
Matthew R. Sydes
Journal of Clinical Oncology, Volume: 35, Issue: 14, Pages: 1530 - 1541
Swansea University Author: John Wagstaff
-
PDF | Version of Record
Download (1.09MB)
DOI (Published version): 10.1200/JCO.2016.69.0677
Abstract
In this multiform, multistage trial 1245 men with high risk locally advanced or metastatic prostate cancer were treated with standard of care hormone therapy (SOCHT) and randomised (2:1:1) to receive SOCHT alone, SOCHT plus celecoxib (cel) or SOCHT plus cele plus zoledronic acid (ZA). Prostate (+/-...
| Published in: | Journal of Clinical Oncology |
|---|---|
| ISSN: | 0732-183X 1527-7755 |
| Published: |
2017
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa33243 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
In this multiform, multistage trial 1245 men with high risk locally advanced or metastatic prostate cancer were treated with standard of care hormone therapy (SOCHT) and randomised (2:1:1) to receive SOCHT alone, SOCHT plus celecoxib (cel) or SOCHT plus cele plus zoledronic acid (ZA). Prostate (+/- pelvic) radiotherapy was encouraged for men with localised disease. In the SOCHT arm median survival was 66 months. The hazard ratio for death in the SOCHT + cel arm was 0.98 (95% CI 0.80 to 1.20, median survival 70 months, p=0.847). The hazard ratio for death in the SOCHT + cel + ZA was 0.86 (95% CI 0.70 to 1.05, median survival 76 months, p=0.13). these data show no overall evidence of improved survival with cel. |
|---|---|
| College: |
Faculty of Medicine, Health and Life Sciences |
| Issue: |
14 |
| Start Page: |
1530 |
| End Page: |
1541 |